Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 13;10:127. doi: 10.3389/fonc.2020.00127

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Carr, Zimmermann, Chiu, Zenke, Blaukat and Vassilev.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

M3814 shows a strong combination benefit with Mylotarg in AML xenograft models. Established subcutaneous MV4-11(group size: 10 mice) and HL-60 (group size: 9 mice) xenograft tumors in immunodeficient mice were treated with Mylotarg (0.1 mg/kg in MV4-11 and 1.0 mg/kg in HL-60, single administration, intravenous injection), M3814 (100 mg/kg, daily, oral gavage), and the combination thereof as indicated. Statistical analysis was performed on log transformed tumor volume data applying a repeated measurement ANOVA with Bonferroni post-test for comparing the groups treated with Mylotarg + M3814 and Mylotarg alone using GraphPad Prism software. CR, complete response.